ImmuneBridge Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
16
- Latest Deal Type
-
Seed
- Latest Deal Amount
-
$7.7M
- Investors
-
16
ImmuneBridge General Information
Description
Developer of allogeneic cellular immunotherapies designed for advancing cancer treatment. The company's immunotherapies utilize proprietary expansion technology to amplify cord blood-derived immune stem cells while maintaining immune multipotency, offering a diverse and consistent cellular source, enabling progenitors with cellular pharmacopeia, and dealing with oncology treatments.
Contact Information
Website
www.immunebridge.comCorporate Office
- 2122 Bryant Street
- San Francisco, CA 94110
- United States
Corporate Office
- 2122 Bryant Street
- San Francisco, CA 94110
- United States
ImmuneBridge Timeline
ImmuneBridge Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Seed Round | 24-Mar-2026 | $7.7M | Completed | Generating Revenue | ||
| 2. Accelerator/Incubator | 16-Oct-2025 | Completed | Generating Revenue | |||
| 1. Seed Round | 09-Jan-2023 | $12M | $12M | Completed | Generating Revenue |
ImmuneBridge Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed I | ||||||||
| Seed I-B | ||||||||
| Seed I-A | 41,041,499 | $0.000100 | 8% | $0.05 | $0.05 | 1x | $0.05 | 10.75% |
| Seed | 28,958,501 | $0.000100 | 8% | $0.07 | $0.07 | 1x | $0.07 | 0% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
ImmuneBridge Patents
ImmuneBridge Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3138280-A1 | Compositions and methods of making expanded hematopoietic stem cells using derivatives of carbazole | Pending | 01-May-2019 | ||
| EP-3962474-A1 | Compositions and methods of making expanded hematopoietic stem cells using derivatives of carbazole | Inactive | 01-May-2019 | ||
| EP-3962474-A4 | Compositions and methods of making expanded hematopoietic stem cells using derivatives of carbazole | Inactive | 01-May-2019 | ||
| US-20220378740-A1 | Compositions and methods of making expanded hematopoietic stem cells using derivatives of carbazole | Inactive | 01-May-2019 | ||
| WO-2020223383-A1 | Compositions and methods of making expanded hematopoietic stem cells using derivatives of carbazole | Inactive | 01-May-2019 | A61K31/403 |
ImmuneBridge Signals
ImmuneBridge Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Immortal Dragons | Venture Capital | Minority | ||
| LongGame Ventures | Venture Capital | Minority | ||
| Sand Hill Angels | Angel Group | Minority | ||
| T.Rx Capital | Venture Capital | Minority | ||
| Endless Frontier Labs | Accelerator/Incubator | Minority |
ImmuneBridge FAQs
-
When was ImmuneBridge founded?
ImmuneBridge was founded in 2018.
-
Where is ImmuneBridge headquartered?
ImmuneBridge is headquartered in San Francisco, CA.
-
What is the size of ImmuneBridge?
ImmuneBridge has 16 total employees.
-
What industry is ImmuneBridge in?
ImmuneBridge’s primary industry is Drug Discovery.
-
Is ImmuneBridge a private or public company?
ImmuneBridge is a Private company.
-
What is ImmuneBridge’s current revenue?
The current revenue for ImmuneBridge is .
-
How much funding has ImmuneBridge raised over time?
ImmuneBridge has raised $19.7M.
-
Who are ImmuneBridge’s investors?
Immortal Dragons, LongGame Ventures, Sand Hill Angels, T.Rx Capital, and Endless Frontier Labs are 5 of 16 investors who have invested in ImmuneBridge.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process